76 related articles for article (PubMed ID: 20578212)
1. Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
Biopharm Drug Dispos; 2010 Jul; 31(5-6):298-315. PubMed ID: 20578212
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
Woo S; Krzyzanski W; Jusko WJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
Ramakrishnan R; Cheung WK; Wacholtz MC; Minton N; Jusko WJ
J Clin Pharmacol; 2004 Sep; 44(9):991-1002. PubMed ID: 15317827
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
Arroliga AC; Guntupalli KK; Beaver JS; Langholff W; Marino K; Kelly K
Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.
Krzyzanski W; Jusko WJ; Wacholtz MC; Minton N; Cheung WK
Eur J Pharm Sci; 2005 Nov; 26(3-4):295-306. PubMed ID: 16102948
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].
Georgopoulos D; Matamis D; Routsi C; Michalopoulos A; Maggina N; Dimopoulos G; Zakynthinos E; Nakos G; Thomopoulos G; Mandragos K; Maniatis A;
Crit Care; 2005 Oct; 9(5):R508-15. PubMed ID: 16277712
[TBL] [Abstract][Full Text] [Related]
11. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.
Woo S; Jusko WJ
Drug Metab Dispos; 2007 Sep; 35(9):1672-8. PubMed ID: 17576810
[TBL] [Abstract][Full Text] [Related]
12. Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients.
Ait-Oudhia S; Vermeulen A; Krzyzanski W
Biopharm Drug Dispos; 2011 Jan; 32(1):1-15. PubMed ID: 21162115
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
[TBL] [Abstract][Full Text] [Related]
14. Use of epoetin alfa in autologous blood donation programs for patients scheduled for elective cardiac surgery.
Walpoth B; Galliker B; Spirig P; Haeberli A; Rosenmund A; Althaus U; Nydegger UE
Semin Hematol; 1996 Apr; 33(2 Suppl 2):75-6; discussion 77. PubMed ID: 8723588
[TBL] [Abstract][Full Text] [Related]
15. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
16. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous epoetin alfa as an adjunct to autologous blood donation before elective coronary artery bypass graft surgery.
Gombotz H
Semin Hematol; 1996 Apr; 33(2 Suppl 2):69-70; discussion 71-2. PubMed ID: 8723587
[TBL] [Abstract][Full Text] [Related]
18. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.
Klaesson S; Ringdén O; Ljungman P; Lönnqvist B; Wennberg L
Bone Marrow Transplant; 1994 Apr; 13(4):397-402. PubMed ID: 8019463
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
